Shilpanjali Jesudason

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Pregnancy Outcomes According to Dialysis Commencing Before or After Conception in Women with ESRD

Shilpanjali Jesudason, B. Grace, Stephen P. McDonald · Clinical Journal of the American Society of Nephrology · 2013 · 159 citations · Full text

An international Delphi survey helped develop consensus-based core outcome domains for trials in peritoneal dialysis

Karine Manera, Allison Tong, Jonathan C. Craig et al. · Kidney International · 2019 · 99 citations · Full text

Hemodialysis, Urology, Health Policy +11

Pregnancy Outcomes for Kidney Transplant Recipients

Melanie Wyld, Philip A. Clayton, Shilpanjali Jesudason et al. · American Journal of Transplantation · 2013 · 98 citations · Full text